Targeting bromodomains: epigenetic readers of lysine acetylation
Nature Reviews Drug Discovery2014Vol. 13(5), pp. 337–356
Citations Over TimeTop 1% of 2014 papers
Related Papers
- → PFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET Bromodomains(2013)245 cited
- → Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734(2020)85 cited
- → Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma(2020)47 cited
- → Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor(2018)16 cited
- → Data from Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734(2023)